Enhancement of suppression oxidative stress and inflammation of quercetin by nano‐decoration for ameliorating silica‐induced pulmonary fibrosis

Abstract

AbstractSilicosis is a life‐threatening lung fibrotic disease caused by excessive inhalation of environmental exposure to crystalline silica‐containing dust, whereas achieving therapeutic cures are constrained. Antioxidation and anti‐inflammation are currently recognized as effective strategies to counteract organ fibrosis. Using naturally occurring phytomedicines quercetin (Qu) has emerged in antagonizing fibrotic disorders involving oxidative stress and inflammation, but unfortunately the hydrophilicity deficiency. Herein, chitosan‐assisted encapsulation of Qu in nanoparticles (Qu/CS‐NPs) was first fabricated for silicosis‐associated fibrosis treatment by pulmonary delivery. Qu/CS‐NPs with spherical diameters of ~160 nm, demonstrated a high Qu encapsulated capability, excellent hydrophilic stability, fantastic oxidation radical scavenging action, and outstanding controlled as well as slow release Qu action. A silicosis rat model induced by intratracheal instillation silica was established to estimate the anti‐fibrosis effect of Qu/CS‐NPs. After intratracheal administration, CS‐NPs markedly enhanced Qu anti‐fibrotic therapy efficacy, accompanying the evident changes in reducing ROS and MDA production to mitigate oxidative stress, inhibiting IL‐1β and TNF‐α release, improving lung histological architecture, down‐regulating α‐SAM levels and suppressing ECM deposition, and thereby ameliorating silica‐induced pulmonary fibrosis. Results manifested that the augmented antioxidant and anti‐inflammatory activities of Qu by CS‐NPs delivery was a result of achieving this remarkable improvement in curative effects. Combined with negligible systemic toxicity, nano‐decorated Qu may provide a feasible therapeutic option for silicosis therapy.